We promote heart health, screening, life support and AEDs in Jersey. Researching community screening with portable devices #heartscreening #AED #CPR #prevention
Fewer islanders are dying young from heart disease in Jersey.
▪️ Premature coronary heart disease deaths down 19% from their peak
▪️ Men living 1.4 years longer than a decade ago
▪️ Avoidable death rate a third lower than England’s
▪️ Life expectancy 83.7 years, two years ahead of England
Public Health Jersey’s 2025 mortality and life expectancy reports are out this week, and there is good news in them.
No single thing explains this, but fewer people smoke, risk factors are found and treated earlier, and heart treatment is faster when things go wrong.
I am proud of the part the Jersey Heart Team has played, through nurse-led prevention, earlier heart failure diagnosis, cardiac rehabilitation, AI in cardiac imaging and our amazing research programme, with support from primary care and public health on lipids, obesity and lifestyle.
The job is not finished. Heart disease is still the leading cause of early death in men, and we are living more years in poorer health. So we are finalising our five-year cardiology strategy “Kokoro”, which sets out our vision of “Caring for Heart and Mind” to help tackle this.
Prevention remains the best investment we can make
gov.je/Government/Pages/Stat…gov.je/Government/Pages/Stat…#JerseyCI#Cardiology#Prevention#JerseyHeartTeam#IslandofLongevity@GovJsyHCJ@CaristoHeart@GovJsyHCJ@TheAllanLab@heartscreening
Thanks to our supporters and families, we held 35 screening days in October with 3,121 young people screened.
CRY's screening events are mostly funded by CRY supporters often in memory of someone who has died from a sudden cardiac death. Help CRY carry out more screening events across the UK by donating, fundraising or sharing this message.
For more information about CRY's cardiac screening programme or to look for an event near you please visit: testmyheart.org.uk to see all our upcoming screenings. #TestMyHeart#RaisingAwareness
Here are my initial thoughts on Lp(a)HORIZON. This is targeted to the people to whom it matters the most, my wonderful PATIENTS over the years in my Lp(a) Clinic. I have done my best to keep you healthy, and for the most part it worked. And I think this is reflected in the results of the Lp(a)HORIZON trial. This is also for those with elevated Lp(a) that been carrying significant anxiety and concern over their elevated levels.
1- Big picture: I do not see Lp(a)HORIZON as a failure, like many Monday morning quarterbacks out there who claim to have known the results all along after all. I see it as a MAJOR SUCCESS for our patients.
2- Why? Because we learned that there may be an alternative to reduce Lp(a) mediated risk: which is to: a) keep LDL-C below 65 or lower; b) keep blood pressure at 120 or lower; c) control all other risk factors as best as possible; d) take your medicines that have proven efficacy regularly.
3- I have called Lp(a)HORIZON testing the “Lp(a) Hypothesis”. Which means we did not know if lowering Lp(a) would benefit patients. If we knew Novartis would not have spent >1 billion dollars to do the trial and the FDA would have approved the drug simply on Lp(a) lowering.
4- Why did we not see a benefit in specifically lowering Lp(a) in Lp(a)HORIZON? I think we need to go back to “first principles” in how Lp(a) causes atherothrombosis. It is a minor contributor to atherosclerosis. It is a major contributor to inflammation, via OxPL. It is also anti-fibrinolytic- NOT pro-thrombotic. That means it contributes to vulnerable plaques but not to “plaque burden”. And it contributes to a blood clots enlarging and occluding blood vessels if clots are already made, but not in making blood clots per se.
5- So if one is intensively treated to remove the nidus for vulnerable plaques and clot formation, like the patients in HORIZON (and in the ongoing trials), then Lp(a) may become quiescent.
6- In my Lp(a) Clinic, this is my summary of how I treat my patients: 75% on statin, 50% of ezetimibe and 50% (!!) on PCSK9i, along with judicious use of aspirin in primary prevention and universal use in secondary prevention. This double/triple/quadruple combo is highly effective. If I see no coronary calcium or evidence of atherosclerosis, I am not aggressive with therapy if otherwise not indicated for another reason.
7- That being said, 1 out of 8 people still had an event in Lp(a) HORIZON. So, we need to figure out why beyond classical lipids and blood pressure. I am already thinking 10 yrs ahead and will have new concepts for this issue in near future.
8- I do not think the Lp(a)HORIZON results apply to Aortic Stenosis, as this is not affected by LDL-C or for the most part aspirin, but is more @OxPL_apoB driven in people with high Lp(a).
I think we owe a huge debt of gratitude for the Lp(a)HORIZON trial, to @novartis and to @ionispharma for leading the Lp(a) field.
And to circle back to people with elevated Lp(a): Lp(a)HORIZON has now armed us with actionable (and inexpensive) knowledge to help people with elevated Lp(a). Take a big breath and sigh of relief, Lp(a) risk can be managed. Treat it like you do other risk factors and your prognosis will be good, like many of my Lp(a) Clinic patients. We do need to do more work to figure out, among those with elevated Lp(a), who are highest risk, and target those in future studies,
I will provide more scientific comments at a later time and will be publishing my thoughts in a journal in the future.
With all that said, we still don't know the physiological function of Lp(a), if any, and why >99.99% have some circulating Lp(a) and why 1 in 5 have very high levels. Knowing this may give us the ultimate answer on Lp(a) and it role not only in CV disease but also in life and longevity. Along with my collaborators, we will have something on this also in near future.
Thank you all for following Lp(a)'s journey in these pages. The story is actually in the middle not at the end...a few more chapters are in the works.
1 in 300 young people that CRY screens will have a potentially life-threatening heart condition. CRY aims to save young lives by offering screening to anyone aged 14-35 thanks to the support and funding of those affected by a young sudden cardiac death. #TestMyHeart
Starting 16 Nov 2026, we are bringing people around the world together to raise awareness of #AtrialFibrillation (AF/AFib). 🔁 Download our social media toolkit for ready-made graphics to share: heartrhythmalliance.org/afa/…#GAFAW2026
AHA 2026 Series | Lp(a): Lowering Lp(a) Isn't Always Enough
A major cardiovascular trial presented at AHA 2026 delivered a disappointing result.
Pelacarsen, a drug designed to lower lipoprotein(a), reduced Lp(a) levels by nearly 78%. Yet this did not translate into fewer heart attacks, strokes, or other major cardiovascular events.
The HORIZON trial included 8,350 patients with established cardiovascular disease and elevated Lp(a).
Key findings:
• Lp(a) dropped nearly 78%.
• Major cardiovascular events were not reduced (HR 1.02).
• Treatment discontinuation was higher with pelacarsen (35.1% vs 18.3%).
Why does this matter?
Lp(a) is largely inherited and is an important cardiovascular risk factor. However, substantial Lp(a) reduction did not translate into clinical benefit in this trial.
My take: Does lowering Lp(a) stabilize existing plaques?
Lp(a) carries oxidized phospholipids that contribute to vascular inflammation and atherosclerosis. Whether lowering Lp(a) changes plaque composition or stabilizes vulnerable plaques remains unproven.
HORIZON was an outcomes trial, not a coronary imaging study. We still need imaging evidence to understand whether Lp(a) reduction changes plaque biology.
Does this mean Lp(a) doesn't matter? Absolutely not.
We still need to understand whether earlier intervention, greater Lp(a) reduction, or newer therapies can translate into meaningful cardiovascular benefits.
Full article: nejm.org/doi/full/10.1056/NE…
Are you aged 14-35? 🏃♂️🏊♀️🏋️♂️
Whether you’re an athlete, a student, or just someone who cares about your health, CRY’s TestMyHeart cardiac screening could be life-saving. It’s quick, free, and could save your life.
Sign up today: testmyheart.org.uk/